Novo Nordisk receives Investment Bank Analyst Rating Update
Inflation worries continue to weigh on equity markets Earnings season will likely increase volatility ETFs offer investors ability to diversify Earnings season has started with...
Reddit-hyped stocks slump Alphabet, Amazon beat on earnings Tech leads reflation trade rally Key EventsUS futures contracts on the Dow, S&P, NASDAQ, and European stocks advanced...
Eli Lilly & Company (NYSE:LLY) announced that the FDA issued a complete response letter (“CRL”) for its supplemental new drug application (sNDA) seeking label...
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
|Average||846.3 (+6.73% Upside)|
|No. of Analysts||25|